Simplified Summary
Survodutide is a synthetic dual agonist peptide that engages both GLP-1 and glucagon receptors. Preclinical studies have investigated its metabolic effects in animal models, with particular attention to liver biology, where the glucagon receptor component may contribute to hepatic fat mobilisation while GLP-1 receptor engagement modulates inflammatory pathways.
Key Findings Reported in Preclinical Models
- Reductions in hepatic steatosis markers in preclinical NASH rodent models, with decreased liver triglyceride content and histological steatosis scores in diet-induced models.
- Attenuation of liver fibrosis-associated markers, including collagen deposition and stellate cell activation markers in rodent NASH models.
- Significant reduction of body weight and adipose tissue mass in diet-induced obesity models using dual-energy X-ray absorptiometry and tissue dissection.
- Modulation of hepatic gene expression profiles in transcriptomic studies examining genes related to lipogenesis, beta-oxidation, and inflammatory cytokines.
- Improved insulin sensitivity indicators in preclinical glucose and insulin tolerance tests in metabolically dysfunctional rodent models.
Introduction
Survodutide was developed as a dual GLP-1 and glucagon receptor agonist, drawing on preclinical evidence that simultaneous activation produces complementary effects on hepatic lipid metabolism and systemic energy balance. Its development was motivated in part by evidence that glucagon receptor agonism promotes hepatic fat oxidation while GLP-1 receptor engagement contributes to insulin sensitisation and anti-inflammatory signalling.
The compound has received particular attention in preclinical NASH research. Rodent models of diet-induced and choline-deficient NASH have been used to characterise effects on the histological hallmarks of liver disease including steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis.
Research Applications
- Preclinical NASH and liver fibrosis model research examining dual GLP-1/glucagon receptor engagement and hepatic steatosis, inflammation, and fibrotic remodelling.
- Adipose tissue biology investigations in diet-induced obesity animal models.
- Hepatic gene expression and metabolomics studies using survodutide as a pharmacological tool.
- Comparative receptor pharmacology research contrasting its activity profile with GLP-1 monoagonists and GLP-1/GIP dual agonists.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.